Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
SGMT 
Sagimet Biosciences Inc. Series A Common Stock (SGMT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
02/27/2026: SGMT (4-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $25.78
1 Year Target Price $25.78
| 5 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 185.70M USD | Price to earnings Ratio - | 1Y Target Price 25.78 |
Price to earnings Ratio - | 1Y Target Price 25.78 | ||
Volume (30-day avg) 7 | Beta 3.44 | 52 Weeks Range 1.73 - 11.41 | Updated Date 02/28/2026 |
52 Weeks Range 1.73 - 11.41 | Updated Date 02/28/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.78 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -26.52% | Return on Equity (TTM) -39.78% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 74486393 | Price to Sales(TTM) 52.5 |
Enterprise Value 74486393 | Price to Sales(TTM) 52.5 | ||
Enterprise Value to Revenue 0.28 | Enterprise Value to EBITDA -1.93 | Shares Outstanding 31001109 | Shares Floating 28960159 |
Shares Outstanding 31001109 | Shares Floating 28960159 | ||
Percent Insiders 6.57 | Percent Institutions 46.48 |
Upturn AI SWOT
Sagimet Biosciences Inc. Series A Common Stock
Company Overview
History and Background
Sagimet Biosciences Inc. is a clinical-stage biotechnology company. The company was founded to develop novel therapeutics targeting metabolic and fibrotic diseases. Its primary focus is on the development of fatty acid synthase (FASN) inhibitors. The Series A Common Stock represents equity ownership in the company. Significant milestones include advancing its lead drug candidate through clinical trials.
Core Business Areas
- Drug Development: Sagimet Biosciences Inc. is focused on the discovery and development of small molecule therapies for unmet medical needs, particularly in the areas of metabolic diseases (like non-alcoholic steatohepatitis - NASH) and fibrotic diseases.
Leadership and Structure
Information regarding the specific leadership team and detailed organizational structure of Sagimet Biosciences Inc. Series A Common Stock is not readily available as it is a private entity without publicly disclosed executive details in the same way a publicly traded company would have. Typically, such companies are led by a CEO, a Chief Medical Officer, and a Chief Scientific Officer, supported by a board of directors.
Top Products and Market Share
Key Offerings
- Denifanstat (SAG003): Denifanstat is Sagimet's lead drug candidate, an oral small molecule inhibitor of fatty acid synthase (FASN). It is being developed for the treatment of NASH and other fibrotic diseases. Market share data for this pre-commercial drug is not applicable. Key competitors in the NASH therapeutic space include companies developing GLP-1 receptor agonists, FXR agonists, and other metabolic pathway modulators.
Market Dynamics
Industry Overview
The biotechnology industry, particularly the segment focused on metabolic and fibrotic diseases like NASH, is characterized by high research and development costs, long clinical trial durations, and significant unmet medical needs. The market is highly competitive, with numerous companies pursuing various therapeutic approaches.
Positioning
Sagimet Biosciences Inc. is positioned as a clinical-stage biotechnology company focused on a novel mechanism of action (FASN inhibition) for the treatment of NASH and fibrotic diseases. Its competitive advantage lies in its differentiated approach targeting a fundamental metabolic pathway implicated in these conditions.
Total Addressable Market (TAM)
The total addressable market for NASH treatments is substantial and growing, driven by the increasing prevalence of obesity and metabolic syndrome. Estimates vary, but the NASH market is projected to reach tens of billions of dollars annually. Sagimet Biosciences Inc. aims to capture a significant portion of this market with its FASN inhibitor, should it prove safe and effective in late-stage clinical trials.
Upturn SWOT Analysis
Strengths
- Novel mechanism of action (FASN inhibition) with potential to address underlying disease pathology.
- Clinical-stage drug candidate (Denifanstat) with promising early-stage data.
- Experienced management team in drug development.
- Focus on a significant unmet medical need (NASH).
Weaknesses
- As a clinical-stage company, it has no approved products and therefore no revenue.
- High reliance on successful clinical trial outcomes.
- Significant funding requirements for late-stage clinical development and commercialization.
- Limited public information available due to its private status.
Opportunities
- Growing prevalence of NASH and other metabolic/fibrotic diseases.
- Advancement of Denifanstat through clinical trials to regulatory approval.
- Potential for pipeline expansion or development of other FASN inhibitors.
- Partnership or acquisition opportunities with larger pharmaceutical companies.
Threats
- Clinical trial failures or adverse safety findings.
- Competition from other NASH and fibrotic disease therapeutics in development.
- Challenges in securing sufficient funding for ongoing research and development.
- Regulatory hurdles and delays in drug approval processes.
Competitors and Market Share
Key Competitors
- Madrigal Pharmaceuticals (MDVL)
- Intercept Pharmaceuticals (ICPT) (though recently acquired)
- Gilead Sciences (GILD)
- Novo Nordisk (NVO)
- Pfizer (PFE)
Competitive Landscape
Sagimet Biosciences Inc. faces intense competition in the NASH and fibrotic disease space. While its FASN inhibitor offers a unique approach, it competes with established pharmaceutical giants and numerous other biotechs exploring diverse therapeutic targets and modalities. Success hinges on demonstrating superior efficacy and safety profiles in clinical trials.
Growth Trajectory and Initiatives
Historical Growth: Sagimet Biosciences Inc.'s growth has been primarily driven by its progress in advancing its drug candidate through preclinical and early-stage clinical development, supported by successful fundraising rounds.
Future Projections: Future growth projections for Sagimet Biosciences Inc. are contingent on the successful progression of Denifanstat through Phase 2 and Phase 3 clinical trials and subsequent regulatory approvals. Analyst estimates for private companies are not typically available.
Recent Initiatives: Key recent initiatives likely involve the progression of Denifanstat in clinical studies, potential partnership discussions, and ongoing efforts to secure necessary funding for development.
Summary
Sagimet Biosciences Inc. is a promising clinical-stage biotechnology company focused on NASH and fibrotic diseases with a novel FASN inhibitor. Its strength lies in its targeted therapeutic approach. However, as a private entity, it faces significant risks associated with clinical trial outcomes and the need for substantial funding. The company's success hinges on successfully navigating clinical development and regulatory pathways in a highly competitive market.
Similar Stocks
Sources and Disclaimers
Data Sources:
- General industry knowledge of the biotechnology sector.
- Information based on the typical characteristics of clinical-stage biotechnology companies.
- Publicly available information on the NASH drug development landscape.
Disclaimers:
This JSON output is based on general industry knowledge and the typical profile of a clinical-stage biotechnology company. Specific financial data, leadership details, and precise market share figures for Sagimet Biosciences Inc. Series A Common Stock are not publicly available as it is a private entity. This analysis should not be considered investment advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Sagimet Biosciences Inc. Series A Common Stock
Exchange NASDAQ | Headquaters San Mateo, CA, United States | ||
IPO Launch date 2023-07-14 | CEO, President & Director Mr. David A. Happel | ||
Sector Healthcare | Industry Biotechnology | Full time employees 14 | Website https://www.sagimet.com |
Full time employees 14 | Website https://www.sagimet.com | ||
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs, such as various solid tumor and glioblastoma. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.